The discovery of Kisqali® (ribociclib), a CDK4/6 inhibitor for the treatment of breast cancer

Seminar | March 19 | 1:30-2:30 p.m. | 775 Tan Hall

 Dr. Christopher Brain, Novartis

 College of Chemistry

 seminarcoordinator-cchem@berkeley.edu, 510-643-0572